What critical skill gaps are emerging in oncology and specialty pharma?
In this specific field and other specialty pharmaceutical areas, scientific innovation is advancing at an unprecedented pace, often outstripping the capacity of traditional talent pipelines. This has led to a growing shortage of professionals with deep expertise in translational science, precision medicine and advanced biologics.
At the same time, the evolving healthcare landscape demands capabilities beyond core scientific research. Organizations increasingly need professionals who can navigate digital health technologies, analyze real-world evidence and manage complex global regulatory environments.
To bridge these gaps, companies are adopting a dual approach. While they continue to attract highly specialized talent from the global market, they are also investing strategically in their existing workforce. Targeted training, continuous learning initiatives and structured upskilling programmes are helping employees develop the skills needed to meet the rapidly evolving demands of healthcare innovation.
This combination of external recruitment and internal talent development is becoming essential for pharmaceutical organizations seeking to maintain leadership in high-complexity therapeutic areas. At Menarini Greece, particular emphasis is placed on preparing leaders to operate across scientific, regulatory and commercial interfaces, ensuring readiness for the complexity of specialty-care environments.
How is the competition for senior scientific and commercial leaders evolving?
Competition for experienced leaders in specialty pharma is intensifying, particularly for those who can bridge the gap between scientific innovation and commercial strategy. Executives with deep scientific expertise, strong business acumen and the ability to navigate complex regulatory landscapes while driving market success are increasingly in high demand.
This competition is truly global. Organizations are expanding their search beyond traditional markets, attracting senior leaders from diverse regions and international ecosystems of innovation.
In this environment, retaining top talent requires more than traditional incentives. Companies are emphasizing flexible career pathways, opportunities to work on breakthrough therapies, and mission-driven cultures that allow leaders to make a tangible impact on patient outcomes.
What distinguishes companies that successfully attract high-impact executives?
Organizations that consistently attract top-tier executives share several key characteristics. They demonstrate a clear and credible commitment to innovation while fostering a culture that balances autonomy with strong cross-team collaboration. Leaders are drawn to environments where they can take ownership, contribute strategically and work alongside high-performing teams.
Employer branding also plays a critical role, particularly when it is authentically tied to the company’s mission and its impact on patients’ lives. Executives are increasingly motivated by opportunities to advance scientific progress while contributing to meaningful, purpose-driven outcomes.
Attracting top executives is only part of the challenge. Leading organizations invest in structured onboarding and executive coaching programmes that enable new leaders to integrate quickly, build strong internal networks and deliver impact early in their tenure.
How do organisations build leadership resilience in complex regulatory environments?
In the pharmaceutical industry, leadership resilience goes beyond managing crises. It demands long-term strategic thinking, a deep understanding of complex regulatory systems, and the ability to make informed decisions under uncertainty and rapidly changing conditions.
To develop this capability, organizations are investing in structured leadership development programmes. These include mentoring initiatives, exposure to international and cross-functional projects and scenario-based training that simulates regulatory, clinical and market challenges.
Such experiences help leaders build the agility, judgment and confidence needed to navigate evolving regulatory landscapes and respond effectively to clinical or operational setbacks.
At Menarini Greece, developing this resilience is closely linked with encouraging cross-affiliate collaboration and providing opportunities for leaders to engage in broader regional and international initiatives.
Is internal succession still viable, or is external executive hiring becoming essential?
Internal succession remains a cornerstone of leadership development, preserving institutional knowledge, reinforcing organizational culture and supporting continuity. However, in highly specialized pharmaceutical areas, succession planning is becoming increasingly selective.
For roles requiring new expertise or fresh strategic perspectives, organizations often look beyond their internal talent pipelines to attract executives with experience across different markets or specialized scientific domains.
The most effective talent strategy balances both approaches. Companies continue to invest in the development of internal leaders while maintaining the flexibility to recruit externally when needed.
About Menarini
The Menarini Group is a leading international pharmaceutical company headquartered in Florence, Italy, with more than 135 years of history. Operating in over 140 countries and supported by a global workforce of more than 17,000 employees, the company focuses on developing and delivering therapies across several key areas such as oncology, cardio-metabolic, anti-infective, respiratory and consumer health products. With a strong commitment to research and innovation, Menarini invests in advanced therapeutic solutions and global healthcare development, combining scientific expertise with a long-standing focus on patient outcomes and quality of care.
In Greece, the Menarini Group is present through Menarini Hellas and Guidotti Hellas, holding a strong position in the healthcare sector and ranking among the leading companies in the Greek pharmaceutical market. With more than 300 employees in Greece, the Group remains committed to sustainable growth, advancing pharmaceutical knowledge, and creating long-term value for both the healthcare system and society.
